Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways
- 2.1k Downloads
To investigate the protective mechanisms of an 85 % pure extract of (−) epigallocatechin gallate (EGCG) in the development of fibrosis, oxidative stress and inflammation in a recently developed dietary-induced animal model of non-alcoholic fatty liver disease (NAFLD).
Female Sprague–Dawley rats were fed with either normal rat diet or high-fat diet for 8 weeks to develop NAFLD. For both treatments, rats were treated with or without EGCG (50 mg/kg, i.p. injection, 3 times per week). At the end, blood and liver tissue samples were obtained for histology, molecular, and biochemical analyses.
Non-alcoholic fatty liver disease (NAFLD) rats showed significant amount of fatty infiltration, necrosis, fibrosis, and inflammation. This was accompanied by a significant expressional increase in markers for fibrosis, oxidative stress, and inflammation. TGF/SMAD, PI3 K/Akt/FoxO1, and NF-κB pathways were also activated. Treatment with EGCG improved hepatic histology (decreased number of fatty score, necrosis, and inflammatory foci), reduced liver injury (from ~0.5 to ~0.3 of ALT/AST ratio), attenuated hepatic changes including fibrosis (reduction in Sirius Red and synaptophysin-positive stain) with down-regulation in the expressions of key pathological oxidative (e.g. nitrotyrosine formation) and pro-inflammatory markers (e.g. iNOS, COX-2, and TNF-α). EGCG treatment also counteracted the activity of TGF/SMAD, PI3 K/Akt/FoxO1, and NF-κB pathways. Treatment with EGCG did not affect the healthy rats.
Epigallocatechin gallate (EGCG) reduced the severity of liver injury in an experimental model of NAFLD associated with lower concentration of pro-fibrogenic, oxidative stress, and pro-inflammatory mediators partly through modulating the activities of TGF/SMAD, PI3 K/Akt/FoxO1, and NF-κB pathways. Therefore, green tea polyphenols and EGCG are useful supplements in the prevention of NAFLD.
KeywordsEGCG NAFLD Fibrosis Oxidative stress Inflammation
- 2.Mendez-Sanchez N, Arrese M, Zamora-Valdes D, Uribe M (2007) Treating nonalcoholic fatty liver disease. Liver int 27:1157–1165Google Scholar
- 4.Yoneda M, Endo H, Nozaki Y, Tomimoto A, Fujisawa T, Fujita K, Yoneda K, Takahashi H, Saito S, Iwasaki T, Yamamoto S, Tsutsumi S, Aburatani H, Wada K, Hotta K, Nakajima A (2007) Life style-related diseases of the digestive system: gene expression in nonalcoholic steatohepatitis patients and treatment strategies. J Pharmacol Sci 105:151–156CrossRefGoogle Scholar
- 7.McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40(Suppl 1):S17–S29Google Scholar
- 8.French SW, Takahashi H, Wong K, Mendenhall CL (1991) Ito cell activation induced by chronic ethanol feeding in the presence of different dietary fats. Alcohol Alcohol Suppl 1:357–361Google Scholar
- 10.Lieber CS, Leo MA, Mak KM, Xu Y, Cao Q, Ren C, Ponomarenko A, DeCarli LM (2004) Model of nonalcoholic steatohepatitis. Am J Clin Nutr 79:502–509Google Scholar
- 11.Zou Y, Li J, Lu C, Wang J, Ge J, Huang Y, Zhang L, Wang Y (2006) High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 79:1100–1107Google Scholar
- 13.Tipoe GL, Ho CT, Liong EC, Leung TM, Lau TY, Fung ML, Nanji AA (2009) Voluntary oral feeding of rats not requiring a very high fat diet is a clinically relevant animal model of non-alcoholic fatty liver disease (NAFLD). Histol Histopathol 24:1161–1169Google Scholar
- 18.Bruno RS, Dugan CE, Smyth JA, DiNatale DA, Koo SI (2008) Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. J Nutr 138:323–331Google Scholar
- 22.Nanji AA, Jokelainen K, Fotouhinia M, Rahemtulla A, Thomas P, Tipoe GL, Su GL, Dannenberg AJ (2001) Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. American journal of physiology. Gastrointest liver physiol 281:G1348–G1356Google Scholar
- 25.Tipoe GL, Leung TM, Liong E, So H, Leung KM, Lau TY, Tom WM, Fung ML, Fan ST, Nanji AA (2006) Inhibitors of inducible nitric oxide (NO) synthase are more effective than an NO donor in reducing carbon-tetrachloride induced acute liver injury. Histol Histopathol 21:1157–1165Google Scholar
- 26.Leung TM, Fung ML, Liong EC, Lau TY, Nanji AA, Tipoe GL (2011) Role of nitric oxide in the regulation of fibrogenic factors in experimental liver fibrosis in mice. Histol Histopathol 26:201–211Google Scholar
- 28.Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ (2005) Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 3:384–389Google Scholar
- 33.Chen JH, Tipoe GL, Liong EC, So HS, Leung KM, Tom WM, Fung PC, Nanji AA (2004) Green tea polyphenols prevent toxin-induced hepatotoxicity in mice by down-regulating inducible nitric oxide-derived prooxidants. American J clin nut 80:742–751Google Scholar
- 40.Chen D, Milacic V, Chen MS, Wan SB, Lam WH, Huo C, Landis-Piwowar KR, Cui QC, Wali A, Chan TH, Dou QP (2008) Tea polyphenols, their biological effects and potential molecular targets. Histol Histopathol 23:487–496Google Scholar
- 41.Frei B, Higdon JV (2003) Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 133:3275S–3284SGoogle Scholar
- 43.Wang F, Wang LY, Wright D, Parmely MJ (1999) Redox imbalance differentially inhibits lipopolysaccharide-induced macrophage activation in the mouse liver. Infect Immun 67:5409–5416Google Scholar
- 44.Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J immunol (Baltimore, Md.: 1950) 173:5794–5800Google Scholar
- 45.Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, Varilek GW (2001) The green tea polyphenol (−)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol 60:528–533Google Scholar
- 46.Lin YL, Lin JK (1997) (−)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 52:465–472Google Scholar
- 49.Shimizu M, Deguchi A, Joe AK, McKoy JF, Moriwaki H, Weinstein IB (2005) EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 5:69–78Google Scholar